Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

 
Press Releases
  Date Title View
Apr 20, 2017
Mateon Announces Initiation of Investigator-Sponsored Phase 1 Study of CA4P in Combination with Everolimus in Neuroendocrine Tumors

SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the Markey Cancer Center at the University of Kentucky has enrolled the first patient into a new pha...

Apr 18, 2017
Mateon Therapeutics Announces Encouraging Results from First Interim Analysis of Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer

No Significant CA4P Drug Safety Issues IdentifiedInitial Efficacy in Favor of CA4P, with 22% of CA4P Patients Responding versus 9% in the Control ArmEnrollment in the Study Continuing SOUTH SAN FRANCISCO, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting ...

Mar 31, 2017
Mateon Therapeutics Announces Abstract Presentations for the American Association for Cancer Research Annual Meeting in April 2017

SOUTH SAN FRANCISCO, Calif., March 31, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that updates on several of its preclinical programs are being presented at the American Association for C...

Mar 30, 2017
Mateon Therapeutics Reviews 2016 Highlights and Reports 2016 Financial Results

SOUTH SAN FRANCISCO, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and announced 2016 financial results.  Corporate Achievements During 2016 Changed...

Mar 15, 2017
Mateon Therapeutics Announces Initial Data from Third Cohort of Phase 1b Study of OXi4503 in Relapsed/Refractory AML

One patient of four (25%) achieved a complete remissionNo dose-limiting toxicities observed and study is progressing into the fourth dose cohort SOUTH SAN FRANCISCO, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orph...

Mar 8, 2017
Mateon Therapeutics to Present at 29th Annual ROTH Conference

SOUTH SAN FRANCISCO, Calif., March 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that it will present a company overview at the 29th Annual ROTH Conference taking place from March 12-15,...

Feb 13, 2017
Mateon Therapeutics Announces Initial Pre-clinical Data on Combination of CA4P with Checkpoint Inhibitors

In one study most animals receiving the combination of CA4P and anti-CTLA4 antibody were tumor free at completionThree additional studies provide evidence that CA4P may enhance anti-CTLA4, anti-PD1, and anti-PD-L1 antibody activity SOUTH SAN FRANCISCO, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmac...

Feb 7, 2017
Mateon Therapeutics to Present at BIO CEO & Investor Conference on February 13, 2017

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that it will present a company overview at the 19th Annual BIO CEO & Investor Conference in New York at 5:...

Jan 20, 2017
Mateon Therapeutics to Present Data on Study OX4218 in Neuroendocrine Tumors at ASCO Gastrointestinal Cancers Symposium

- Data Shows Additional Evidence of CA4P Activity -- Investigator-sponsored Study Initiating, Based on OX4218 Results - SOUTH SAN FRANCISCO, Calif., Jan. 20, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indicatio...

Dec 7, 2016
Mateon Common Stock to Trade on OTCQX Beginning on December 8, 2016

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that shares of its common stock will be eligible for trading on the OTCQX Market, effective with the open...

FirstPrevious
2
...
NextLast
= add release to Briefcase